There are limited data for the clinical efficacy of bebtelovimab in preventing severe coronavirus disease 2019. Among outpatients unable to take nirmatrelvir-ritonavir at a large health system, 10 of 377 (2.7%) patients who received bebtelovimab and 17 of 377 (4.5%) matched untreated patients were hospitalized or died. The 43% observed risk reduction with bebtelovimab was not statistically significant ( = 0.14).
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9620388 | PMC |
| http://dx.doi.org/10.1093/ofid/ofac565 | DOI Listing |
Publication Analysis
Top Keywords
large health
8
health system
8
bebtelovimab
4
bebtelovimab high-risk
4
high-risk outpatients
4
outpatients early
4
early covid-19
4
covid-19 large
4
system limited
4
limited data
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!